UK markets closed
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • FTSE 250

    20,910.37
    -287.75 (-1.36%)
     
  • AIM

    1,183.25
    -8.61 (-0.72%)
     
  • GBP/EUR

    1.1532
    +0.0034 (+0.30%)
     
  • GBP/USD

    1.3922
    -0.0091 (-0.65%)
     
  • BTC-GBP

    32,305.50
    -1,232.57 (-3.68%)
     
  • CMC Crypto 200

    912.88
    -20.25 (-2.17%)
     
  • S&P 500

    3,811.15
    -18.19 (-0.48%)
     
  • DOW

    30,932.37
    -469.64 (-1.50%)
     
  • CRUDE OIL

    61.66
    -1.87 (-2.94%)
     
  • GOLD FUTURES

    1,733.00
    -42.40 (-2.39%)
     
  • NIKKEI 225

    28,966.01
    -1,202.26 (-3.99%)
     
  • HANG SENG

    28,980.21
    -1,093.96 (-3.64%)
     
  • DAX

    13,786.29
    -93.04 (-0.67%)
     
  • CAC 40

    5,703.22
    -80.67 (-1.39%)
     

Global Latent TB Detection Market Forecast to 2027 - COVID-19 Impact and Analysis

Research and Markets
·8-min read

Dublin, Feb. 08, 2021 (GLOBE NEWSWIRE) -- The "Latent TB Detection Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Test (Tuberculin Skin Test (TST) and Interferon Gamma Released Assay (IGRA)); End User (Hospitals, Diagnostic Centers, Laboratories, and Others) and Geography" report has been added to ResearchAndMarkets.com's offering.

According to this report the global latent TB market is expected to reach $1,684.86 million in 2027 from $1,131.82 million in 2019. The market is estimated to grow with a CAGR of 5.2% from 2020-2027. The growth of the market is attributed to the increasing prevalence of tuberculosis and government initiatives to promote tuberculosis detection. However, multi drug resistant tuberculosis (MDR-TB) is likely to hamper the growth of the market to a certain extent.

Based on test, the latent TB detection market was segmented into tuberculin skin test (TST) and interferon gamma released assay (IGRA). In 2019, the tuberculin skin test (TST) segment accounted for the highest share in the market and is likely to retain its dominant share. The TST results are obtained in around 48-72 hours. Reading the presence or absence as well as the amount of in duration known as localized swelling does the reading of the test. Although TST is a basic test performed in high volumes, the inaccuracy in detection is likely to hamper the growth of the segment during the coming years. On the other hand, the interferon gamma released assay (IGRA) is expected to witness fastest growth in the market owing to the accuracy obtained through these tests.

Tuberculosis (TB) can stay dormant for years before developing into an active TB disease. This condition is known as latent TB. Diagnosis of latent TB is imperative, as it will develop into infectious TB disease when the immune system becomes weak. The World Health Organization (WHO) stated that a total of 1.4 million people died from TB in 2019, making TB one of the top 10 causes of mortality in the world. The data also stated that in 2019 TB affected 10 million people in the world, of which 56% were adult males, 32% were adult females, and 12% were children. The disease is prevalent in all age groups worldwide. Furthermore, according to the Global Health Education (GHE), a UK-based registered charity, the high TB burden countries accounted for 86% of the estimated cases worldwide. India, Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh, and South Africa are among the countries that are highly affected with TB. Therefore, the high prevalence of TB is driving the need for TB tests, in turn, propelling the growth of the latent TD detection market.

The COVID-19 pandemic was first reported in December 2019 in Wuhan (China). The COVID-19 pandemic has threatened the national TB programs worldwide. The WHO have also notified that pandemic is threatening to reverse global progress against tuberculosis. The COVID-19 response has affected multiple sectors of public health, recommended preventive screening, and clinical care around the globe.

QIAGEN, BioMeriux S.A., F. Hoffmann La-Roche Ltd., BD, ARKRAY, Inc., Abbott, Serum Institute of India Pvt. Ltd, Oxford Immunotec Ltd, Lionex GmbH are among the leading companies in the latent TB detection market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the latent TB detection market.

  • Highlights key business priorities in order to assist companies to realign their business strategies.

  • The key findings and recommendations highlight crucial progressive industry trends in the global latent TB detection market, thereby allowing players across the value chain to develop effective long-term strategies.

  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Key Topics Covered:

1. Introduction
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 Latent TB Detection Market - By Test
1.3.2 Latent TB Detection Market - By End User
1.3.3 Latent TB Detection Market - By Geography

2. Latent TB Detection Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Latent TB Detection Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America - PEST Analysis
4.2.2 Europe - PEST Analysis
4.2.3 APAC - PEST Analysis
4.2.4 MEA - PEST Analysis
4.2.5 SCAM - PEST Analysis

5. Latent TB Detection Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Tuberculosis
5.1.2 Government Initiatives to Promote Tuberculosis Detection
5.2 Market Restraints
5.2.1 Emergence of Multidrug Resistant Tuberculosis (MDR-TB)
5.3 Market Opportunities
5.3.1 Emerging Markets
5.4 Future Trends
5.4.1 Advancements in Tuberculosis Diagnosis
5.5 Impact Analysis

6. Latent TB Detection Market - Global Analysis
6.1 Global Latent TB Detection Market Revenue Forecast And Analysis
6.2 Global Latent TB Detection Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players

7. Latent TB Detection Market Analysis - By Test
7.1 Overview
7.2 Latent TB Detection Market Share, by Test, 2019 and 2027 (%)
7.4 Tuberculin Skin Test (TST)
7.4.1.1 Overview
7.4.1.2 Tuberculin Skin Test (TST): Latent TB Detection Market - Revenue and Forecast to 2027 (US$ Million)
7.5 Interferon Gamma Released Assay (IGRA)
7.5.1.1 Overview
7.5.1.2 Interferon Gamma Released Assay (IGRA): Latent TB Detection Market - Revenue and Forecast to 2027 (US$ Million)

8. Latent TB Detection Market Analysis - By End User
8.1 Overview
8.2 Latent TB Detection Market Share, by End User, 2019 and 2027 (%)
8.4 Hospitals
8.4.1.1 Overview
8.4.1.2 Hospitals: Latent TB Detection Market - Revenue and Forecast to 2027 (US$ Million)
8.5 Diagnostic Centers
8.5.1.1 Overview
8.5.1.2 Diagnostic Centers: Latent TB Detection Market - Revenue and Forecast to 2027 (US$ Million)
8.5.2 Laboratories
8.5.2.1 Overview
8.5.2.2 Laboratories: Latent TB Detection Market - Revenue and Forecast to 2027 (US$ Million)
8.5.3 Others
8.5.3.1 Overview
8.5.3.2 Others: Latent TB Detection Market - Revenue and Forecast to 2027 (US$ Million)

9. Latent TB Detection Market Analysis and Forecasts To 2027 - Geographical Analysis
9.1 North America: Latent TB Detection Market
9.2 Europe: Latent TB Detection Market
9.3 Asia Pacific: Latent TB Detection Market
9.4 Middle East & Africa: Latent TB Detection Market
9.5 South and Central America: Latent TB Detection Market

10. Impact of COVID-19 Pandemic on Global Latent TB Detection Market
10.1 North America: Impact Assessment of COVID-19 Pandemic
10.2 Europe: Impact Assessment Of COVID-19 Pandemic
10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
10.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

11. Latent TB Detection Market - Industry Landscape
11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview

12. Company Profiles
12.1 QIAGEN
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 bioMerieux SA
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. HOFFMANN-LA ROCHE LTD.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 BD
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Abbott
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Oxford Immunotec Ltd
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Lionex GmbH
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 ARKRAY, Inc.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Serum Institute of India Pvt. Ltd
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments

13. Appendix
13.1 About the Publisher
13.2 Glossary of Terms

For more information about this report visit https://www.researchandmarkets.com/r/k9lfo0

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900